This presentation will review the rapid progress that investigators have made isolating very potent human monoclonal antibodies for SARS-CoV-2 from the B cells of survivors and deploying them to the clinic.

Speaker:

James Crowe, Jr., M.D.
Director, Vanderbilt Vaccine Center
Vanderbilt University Medical Center

Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery libraries including both (1) highly diverse synthetic naïve antibody phage display libraries and (2) target class specific antibody phage display libraries against difficult-to-drug targets.  In this talk, Aaron Sato, CSO, will present several POC data on each member of their Library of Libraries.  For some of the targets, the power of selecting multiple libraries against each target will be highlighted.

Speaker:

Aaron K. Sato, Ph.D.
Chief Scientific Officer
Twist Bioscience

Antibody discovery research generates copious amounts of data representing complex relationships between sequences, clones, samples and many other entities. Data for these entities, and the processes underlying their generation, represent the core intellectual property (IP) of an antibody discovery program. Success of these programs relies critically on high data quality and robust IP protection, that is best provided with a comprehensive scientific informatics system. This presentation will provide details of the essential elements of such a system for antibody discovery.

抗体開発では、配列、クローン、サンプル、その他多くのエンティティ間の複雑な関係を示す膨大な量のデータが生成されます。このような研究データとその生成プロセスは、抗体開発の中核をなす重要な知的財産です。実験の「再現性の危機」が叫ばれる中、データ品質を向上させ、知的財産を適切に保護するにはどうすれば良いでしょうか。本プレゼンテーションでは、弊社のインフォマティクス・ソリューションをご紹介し、データ品質の向上と知的財産の保護の重要性について日本語字幕付きで配信します。

Speaker:

Andrew LeBeau, Ph.D.
Associate Vice President, Biologics Marketing
Dotmatics

We evaluated the biophysical properties of 400 human B cell-derived mAbs using high-throughput screening assays. Overall, mAbs derived from memory B cells and long-lived plasma cells (LLPCs) display reduced levels of polyreactivity, hydrophobicity, and thermal stability compared with naive B cell-derived mAbs. Somatic hypermutation (SHM) is inversely associated with all three biophysical properties. The developability profiles of the human B cell-derived mAbs are comparable with those observed for clinical mAbs.

Speaker:

Laura Walker, Ph.D.
Director of Antibody Sciences
Adimab LLC

We are aiming to create lasting value for our society in support of worldwide biological communities. We strive to provide more cost-effective service and product to accelerate the scientific research in drug discovery, food and agriculture, etc.

Speaker:

Kevin Zheng
Technical Manager
Gene Universal Inc.

Rapid Novor is the world leader in protein sequencing using mass spectrometry, having sequenced thousands of monoclonal antibodies and proteins over the past 6 years. In 2020 they unveiled their latest service offering, polyclonal antibody protein sequencing which has enabled them to sequence the most abundant and high affinity monoclonal antibodies within the poly mix. With significant interest in the diagnostic and reagent antibody space the technology aims to solve problems for pre-clinical therapeutics groups and diagnostic teams. Come see more about the use cases behind their technology in this webinar.

Speaker:

Anthony Stajduhar
Director of Business Development
Rapid Novor

• Proteins have personalities which are governed by physico-chemical properties. These influence behaviors such as self-association and propensity to aggregate which can impact on safety, efficacy and long-term stability.
• Monitoring such properties can be challenging but is critical to the development of suitable formulations from commencing early process development through to manufacturing.
• This case study for an engineered monoclonal antibody shows how sub-visible particle analysis, composition gradient multi-angle light scattering and dynamic light scattering reveal features which may be missed by other biophysical techniques.

Speaker:

Francisco Gonzalez, PhD
Associate Principal Scientist- Analytical and Formulation Development
Fujifilm Diosynth Biotechnologies

REGN4018 binds both MUC16 on tumor cells and CD3 on T cells. REGN4018 inhibited growth of human tumors in a xenogenic model and syngeneic models. Immuno-PET imaging demonstrated localization of REGN4018 in MUC16-expressing tumors as well as in T cell-rich organs. Toxicology studies in cynomolgus monkeys showed minimal and transient increases in serum cytokines and C-reactive protein following REGN4018 administration with no overt toxicity.

Speaker:

Alison Crawford, Ph.D.
Senior Staff Scientist, Oncology and Angiogenesis
Regeneron Pharmaceuticals

In three weeks, AbCellera discovered, characterized and selected hundreds of antibodies against SARS-CoV-2 from one of the first U.S. patients to recover from COVID-19. AbCellera’s technology stack combines AI-assisted high-throughput single B cell screening with immune repertoire profiling of natural immune responses. Bioinformatic analysis of the resulting panels of antibodies allowed for the rapid characterization of neutralizing antibodies and the identification of therapeutic lead candidates including bamlanivimab.

Speaker:

Kevin Heyries, Ph.D.
Co-Founder and Head of Business Development
AbCellera